Annual and Special Shareholders Meeting of ZoomMed Inc.

ZoomMed Inc. (TSX VENTURE:ZMD), announces it has held its Annual and Special
Meeting of Shareholders as at November 29, 2013.


The purpose of the meeting was:



--  To receive the consolidated financial statements of ZoomMed for the
    fiscal year ended May 31, 2013 and the independent auditors' report; 

--  To elect the board of directors composed of: 
    
    --  Micheline Luneau 
    --  Andre Marmet 
    --  Yves Marmet 
    --  Nicolas Matziorinis 
    --  Bruno Floriani 
    --  Marie-Helene Pinard 
    --  Robert Powell 

--  To appoint Mazars Harel Drouin as the independent auditor and authorize
    the directors to fix their remuneration; 

--  To approve ZoomMed's stock option plan, a 10% rolling stock option plan;



About ZoomMed

The Company builds and operates "ZoomMed's communication network", a clinical
information exchange platform between physicians and the various other
stakeholders of the healthcare sector, such as pharmacists, specialists,
pharmaceutical corporations, laboratories, specialized clinics and others. The
cornerstone of this network is ZoomMed's "ZRx Prescriber", a technological
innovative Web application that enables physicians to use a wireless device,
such as IPhone(TM), IPad(TM), Google Android(TM) or computers, to write and
rapidly deliver scripts. Since it is a stand-alone product, it can easily be
integrated to any Electronic Medical Record application (EMR).


The Company also offers "PraxisLab", a new pharmacy management software that
enhances all aspects of the prescription filling process and the complete
pharmacy patient file management.


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release. Statements made in this news release
that are not historical facts are "forward-looking statements" and readers are
cautioned that any such statements are not guarantees of future performance, and
that actual developments or results, may vary materially from those in these
"forward-looking" statement.


FOR FURTHER INFORMATION PLEASE CONTACT: 
ZoomMed
Mr. Yves Marmet
President and Chief Executive Officer
[phone], Ext 228
[e-mail]
www.zoommed.com